Literature DB >> 14716729

Designing a large prevention trial: statistical issues.

Richard J Kryscio1, Marta S Mendiondo, Frederick A Schmitt, William R Markesbery.   

Abstract

Recent research in Alzheimer's disease (AD) is centred about the early detection and prevention of this disease. Several recent moderate size clinical trials targeted at high risk cohorts have been designed along this theme. There have been few attempts to design a large trial to prevent this disease in elderly individuals at low risk for the disease. The purpose of this paper is to suggest a framework for designing a simple, large AD prevention trial. This framework uses a discrete time hazard model for decreasing the incidence of AD when participants are randomly assigned to one or more active prevention agents or placebo. This design allows for differential incidence among participants due to age, family history, genetic disposition, and ethnicity. It takes into account the length of the follow-up period, participant mortality, drop-outs, drop-ins, and loss to follow-up. This framework is illustrated by PREADVISE, a recently initiated large add-on prevention trial investigating the use of anti-oxidants for preventing AD among men enrolled in a even larger prostate cancer prevention study, SELECT. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14716729     DOI: 10.1002/sim.1716

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  23 in total

1.  Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.

Authors:  Todd E Golde; Lon S Schneider; Edward H Koo
Journal:  Neuron       Date:  2011-01-27       Impact factor: 17.173

2.  Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).

Authors:  Richard J Kryscio; Erin L Abner; Allison Caban-Holt; Mark Lovell; Phyllis Goodman; Amy K Darke; Monica Yee; John Crowley; Frederick A Schmitt
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

3.  A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial.

Authors:  R J Kryscio; E L Abner; F A Schmitt; P J Goodman; M Mendiondo; A Caban-Holt; B C Dennis; M Mathews; E A Klein; J J Crowley
Journal:  J Nutr Health Aging       Date:  2013-01       Impact factor: 4.075

4.  Optimum Design of Disease-modifying Trials on Alzheimer's Disease.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; Ling Chen; Yan Yan
Journal:  Stat Biopharm Res       Date:  2012-08-30       Impact factor: 1.452

5.  University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology.

Authors:  Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

6.  Quality of education and memory test performance in older men: the New York University Paragraph Recall Test normative data.

Authors:  Melissa Mathews; Erin Abner; Allison Caban-Holt; Brandon C Dennis; Richard Kryscio; Frederick Schmitt
Journal:  Curr Alzheimer Res       Date:  2013-09       Impact factor: 3.498

7.  Optimizing parameters in clinical trials with a randomized start or withdrawal design.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; John C Morris
Journal:  Comput Stat Data Anal       Date:  2014-01-01       Impact factor: 1.681

Review 8.  Regulation and function of selenoproteins in human disease.

Authors:  Frederick P Bellinger; Arjun V Raman; Mariclair A Reeves; Marla J Berry
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

Review 9.  Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges.

Authors:  John M Ringman; Joshua Grill; Yaneth Rodriguez-Agudelo; Mireya Chavez; Chengjie Xiong
Journal:  Alzheimers Dement       Date:  2009-03       Impact factor: 21.566

10.  Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Authors:  Gerda G Fillenbaum; Gerald van Belle; John C Morris; Richard C Mohs; Suzanne S Mirra; Patricia C Davis; Pierre N Tariot; Jeremy M Silverman; Christopher M Clark; Kathleen A Welsh-Bohmer; Albert Heyman
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.